CRO QED Clinical Services has created a wholly owned subsidiary, QED Clinical Services India Private Limited, in Ahmedabad, India, to enhance its global delivery of clinical trials.

The subsidiary adds operational and therapeutic expertise to QED, and expands its capacity and capability to offer more global coverage.

QED operations in India will be spearheaded by country head and director of operations Ali Saijad Bohra, who has led clinical monitoring, FSP models and project management across India, South East Asia, Japan, South Korea and Australia. 

“India and the Asia Pacific region will continue to have focus and will remain key markets for the drug development activities for biopharmaceutical companies on account of a variety of benefits,” said Bohra.

In addition to conducting trials in India, QED India will act as a hub for QED’s Asia Pacific operations for control and oversight of its local partners across the region.

“The creation of QED Clinical, India means that we can better meet the global development needs of our sponsors by giving access to vast patient populations via regional experts on the ground,” said CEO Thomas Ogorka. “India continues to receive great focus as an emerging territory and QED’s presence here means we can leverage its high-quality capabilities.”